Project Grant R21CA312323
Award Date 8/12/26
Completion Date 7/30/28
Dollars Obligated $411K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded Beth Israel Deaconess Medical Center, Inc. $681,200 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate mechanisms of resistance to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer and test strategies to overcome that resistance. The project tests whether CD74-positive drug-tolerant persister cells drive acquired resistance to osimertinib and other third-generation EGFR tyrosine kinase inhibitors. The...
- The National Cancer Institute awarded The University of Texas Health Science Center at San Antonio $609,846 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research targeting mucin-type O-glycosylation in EGFR mutant non-small cell lung cancer. The project runs through March 31, 2031, with place of performance in San Antonio, Texas. The work addresses treatment resistance in EGFR-mutant non-small cell lung cancer patients, who initially respond well to...
- The National Institutes of Health National Cancer Institute awarded H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. $433,256 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify new protein targets and chemical leads that address epithelial-to-mesenchymal transition (EMT)–mediated resistance in EGFR-mutant lung cancer. The project applies fragment-based drug discovery to probe previously inaccessible binding sites and expand the biological...
- The National Cancer Institute awarded Health Research, Inc. Roswell Park Division $719,951 on June 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate mechanisms underlying lung cancer lineage plasticity and adaptive resistance to EGFR tyrosine kinase inhibitor therapy. The research addresses a gap in understanding how transcriptional plasticity—reversible and dynamic gene expression adaptations—accelerates acquired EGFR TKI resistance in EGFR-mutant lung...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- Federal Project Grant Award Summary Baylor College of Medicine received a $411,404 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) awarded on August 20, 2025, with a completion date of July 31, 2027. This research initiative aims to identify genes with a significant deficit of loss-of-function (LOF) mutations in lung tumors, a novel approach to cancer-related gene identification. The project utilizes statistical regression modeling and...
- The National Institutes of Health Office of the Director awarded the University of California, San Diego $120,000 on July 1, 2026, under the Research Infrastructure Programs (CFDA 93.351) to establish pre-clinical models of osimertinib resistance-mediated brain metastasis in non-small cell lung cancer. The project will develop orthotopic non-small cell lung cancer mouse models of acquired osimertinib resistance with brain metastases and circulating tumor cells. Aim 1 establishes and...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas Health Science Center at Houston $635,948 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate phospholipase D1 (PLD1) and transferrin receptor 1 (TFR1) as therapeutic targets in chromosome 3q-amplified non-small cell lung cancer. The project will define the mechanisms by which PLD1 promotes NSCLC progression and tumor microenvironment...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...